Hodgkin's lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in ...

An expert discusses that this case of a 60-year-old man with primary refractory diffuse large B-cell lymphoma highlights the ...

Objective To evaluate the cost-effectiveness of polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse ...

LUGANO, Switzerland — The advent of the Pola-R-CHP (polatuzumab plus R-CHOP) regimen has shaken up the long-held standard of R-CHOP in the treatment of diffuse large B-cell lymphoma (DLBCL) and ...

An agent that may fulfill these requirements is the glycan-binding protein Galectin-9 (Gal-9). Indeed, treatment with Gal-9 reduced total cell counts and cell viability of various B cell NHL cell ...